Liquid purification or separation – Filter – Material
Patent
1994-10-06
1998-01-27
Lilling, Herbert J.
Liquid purification or separation
Filter
Material
210646, 21050022, 21050023, 21050027, 2105003, 21050035, 21050041, 21050043, 424529, 530380, A61M 116, B01D 1300
Patent
active
057118817
DESCRIPTION:
BRIEF SUMMARY
DESCRIPTION
TECHNICAL FIELD
The present invention relates to hematopoietic inhibiting factor-containing compositions which inhibit colony formation of colony forming unit-erythroidan erythroid colony forming cell (hereinafter referred to as CFU-E).
BACKGROUND ART
It is reported that the volume of packed red cells (hematocrit) in the majority of patients under therapeutic hemodialysis is 20-30%, which shows an extreme anemic condition compared to the hematocrit of 40-50% in a healthy subject. Meanwhile, erythropoietin, a hemopoietic stimalator has been developed and its massive administration, with the dosage amounting to 30 times the concentration in blood of a healthy subject, has been known to improve the anemia. What has been made clear recently is that though the massive administration of the erythropoietin improves anemia in many patients, some of the patients are left unimproved.
Considering that the massive administration of the hemopoietic stimulating erythropoietin is required, and that there are still some patients whose anemic conditions are left unimproved even by such massive administration of erythropoietin, it can be deemed that a hematopoietic inhibiting substance might be stored in a hemodialysis patient to interfere the activity of the erythropoietin.
Regarding the hematopoietic inhibiting substance, there is a report of Saito et al. (Clinical Chemistry, A. Saito et al. (1986) P1938), for example, wherein they have reported that a hematopoietic inhibiting factor had a molecular weight of 1,000-10,000. If the hematopoietic inhibiting factor had such a molecular weight, the anemia of the hemodialysis patients should have been sufficiently improved by the dialysis utilizing a dialysis membrane used in the present therapeutic hemodialysis which could remove a medium molecular weight substance, however, actually their anemia has not been fully improved yet.
The invention of this application is aimed at solving the above-described problems of the known art, accordingly, its object is to provide accurate hematopoietic inhibiting factor-containing compositions which inhibit colony formation of CFU-E.
DISCLOSURE OF THE INVENTION
The invention of this application relates to hematopoietic inhibiting factor-containing compositions, which are obtained by separating a component having a molecular weight of 200,000 or more from a dialysate obtained by dialyzing blood with a dialysis membrane of a sieving coefficient of not less than 0.01. More specifically, it relates to hematopoietic inhibiting factor-containing compositions which inhibit colony formation of CFU-E, comprising compositions obtained in a fraction eluting at exclusion limit (first fraction) by gel filtration using a gel having maximum molecular weight fractionation of not less than 200,000 and not more than 1,500,000, of a dialysate of blood which is obtained with a dialysis membrane having albumin sieving coefficient of not less than 0.01, followed by concentration with a membrane having molecular weight fractionation of not more than 5,000.
It further relates to a process of treating blood in which AI component is so removed as to satisfy AI/AA.gtoreq.1/50, wherein AI is the height of the absorbancy value of the hematopoietic inhibiting factor-containing compositions according to claims 1-5 and AA is the height of the maximum absorbancy value in a gel filtration pattern of solutes of the dialysate expressed in terms of the absorbancy at 280 nm, and to a dialysis membrane which satisfies AI/AA.gtoreq.1/50, wherein AI is the height of the absorbancy value of the hematopoietic inhibiting factor-containing compositions according to claims 1-5 and AA is the height of the maximum absorbancy value in a gel filtration pattern of solutes of the dialysate expressed in terms of the absorbancy at 280 nm. It further relates to drug compositions and a therapeutic agent for erythrocytosis, containing such hematopoietic inhibiting factor as the active ingredient.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a chart showing a gel filtration
REFERENCES:
patent: 4925534 (1990-05-01), Kataoka et al.
Kataoka Hiroshi
Yamada Satoko
Lilling Herbert J.
Toray Industries Inc.
LandOfFree
Hematopoietic inhibiting factor containing compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hematopoietic inhibiting factor containing compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hematopoietic inhibiting factor containing compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-339235